- Our Story
- Our Methods
- Quality Improvement
- Health Systems Strengthening
- Global Health Security
- Social and Behavior Change Communication
- Research and Evaluation
- HIV and AIDS
- Malaria and Zika
- Maternal, Newborn, and Child Health
- Noncommunicable Diseases
- Reproductive Health and Family Planning
- Vulnerable Children and Families
- Water, Sanitation, and Hygiene
- Our Projects
- Our Resources
- Join Our Team
Antenatal Corticosteroids for Management of Preterm Birth
File Type .jpg | File Size 83.15 KB
Preterm birth complications are the leading cause of deaths for children under five years. Antenatal corticosteroids (ACS) are effective at reducing mortality and serious morbidity among infants born at <34 weeks gestation.
WHO guidelines strongly recommend use of ACS for women at risk of imminent preterm birth where gestational age, imminent preterm birth, and risk of maternal infection can be assessed, and appropriate maternal/newborn care provided. However, coverage remains low in high-burden countries, for reasons that had not been investigated systematically.
"Antenatal Corticosteroids for Management of Preterm Birth: A Multi-Country Analysis of Health System Bottlenecks and Potential Solutions" includes findings and recommendations for leadership and governance, health financing, health workforce, essential medical products and technologies, health service delivery, health information systems, and community ownership and partnership. The article appeared in the BMC Pregnancy and Childbirth Journal supplement, Every Woman, Every Newborn. URC's Jorge Hermida contributed.